Current Pharmaceutical Therapies for Meibomian Gland Dysfunction: From Basic Research to Clinical Practice

Area of Science:

• Ophthalmology
• Dry Eye Disease Research
• Meibomian Gland Dysfunction Therapeutics

Background:

• Meibomian gland dysfunction (MGD) is a primary cause of evaporative dry eye, characterized by gland obstruction and altered secretions.
• This condition leads to tear film instability, ocular inflammation, and irritation.

Purpose of the Study:

• To summarize current pharmaceutical therapies for MGD.
• To analyze these therapies based on their mechanisms: ameliorating microenvironment, inhibiting keratinization, regulating secretory function, and targeting stem cells.
• To discuss the applications, limitations, and future perspectives of pharmaceutical treatments for MGD.

Main Methods:

• Review of basic and clinical research on pharmaceutical therapies for MGD.
• Categorization of therapies based on their functional targets.
• Discussion of existing evidence and future research directions.

Main Results:

• Pharmaceutical therapies show potential in treating MGD through various mechanisms.
• Specific approaches target the ocular surface microenvironment, keratinization processes, glandular secretion regulation, and stem cell therapies.
• Current treatments have demonstrated efficacy but also present limitations that warrant further investigation.

Conclusions:

• Pharmaceutical interventions represent a promising avenue for managing MGD and evaporative dry eye.
• Further research is needed to optimize existing therapies and develop novel treatments targeting the complex pathophysiology of MGD.
• A multi-faceted approach combining pharmaceutical and physical therapies may offer the best outcomes for patients.